Lower UTI Dysfunction Often Not Thoroughly Evaluated in Neurogenic Bladder
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, June 30, 2023 -- For pediatric patients with neurogenic bladder (NGB), lower urinary tract dysfunction is often not thoroughly evaluated, according to a study recently published in the Journal of Clinical Medicine.
Takeya Kitta, M.D., Ph.D., from Asahikawa Medical University in Japan, and colleagues conducted a retrospective, observational study involving NGB patients aged ≤17 years over a 12-month follow-up period to clarify the current status of diagnosis and treatment of NGB. Data were included for 1,065 pediatric NGB patients; 38.9 percent had spina bifida.
Renal/bladder ultrasound was commonly performed (38.3 percent), while urodynamics was rarely used (3.0 percent). The researchers found that anticholinergics were the most frequently used of the overactive bladder medications (17.9 percent of patients) and most patients used these alone, without combination therapy. Overall, 9.3 percent of patients underwent clean intermittent catheterization (alone or in combination with medications); 3.9 percent were treated with medications concurrently. Lower urinary tract infection was the most common incident complication (18.1 percent), which was especially common for those with open spina bifida (54.1 percent).
"Overall, our study shows that in routine clinical practice, lower urinary tract dysfunction is not often assessed per the recommendations from the guidelines," the authors write. "Without adequate evaluation, there is an increased risk of not appropriately identifying disease status, and therefore timely and appropriate treatment may not be provided."
One author is an employee of Pfizer Japan, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
FDA Approves New Antibiotic, Pivya, for Uncomplicated Urinary Tract Infections
TUESDAY, April 30, 2024 -- The U.S. Food and Drug Administration has approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract...
Computer Prompts Could Reduce Empiric Antibiotic Use for UTI
FRIDAY, April 19, 2024 -- For non-critically ill patients with urinary tract infection (UTI), computerized provider order entry (CPOE) prompts providing patient- and...
Transcutaneous Tibial Nerve Stimulation Device Beneficial in Overactive Bladder
TUESDAY, April 2, 2024 -- For patients with overactive bladder (OAB) symptoms, a wearable, smartphone-controlled, rechargeable transcutaneous tibial nerve stimulation (TTNS)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.